Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.

Original publication

DOI

10.1185/03007995.2015.1027183

Type

Journal article

Journal

Curr Med Res Opin

Publication Date

05/2015

Volume

31

Pages

1041 - 1045

Keywords

Chondroitin, Glucosamine, Hyaluronic acid, Osteoarthritis, Symptomatic slow-acting drugs in osteoarthritis, Antirheumatic Agents, Delayed-Action Preparations, Evidence-Based Medicine, Humans, Osteoarthritis, Knee, Practice Guidelines as Topic